JZP-8 is a novel drug delivery formulation incorporating clonazepam, a widely prescribed benzodiazepine. The product candidate is designed to be a fast-acting intranasal spray for the treatment of recurrent acute repetitive seizures in patients with epilepsy.
In December 2007, Jazz Pharmaceuticals dosed the first patient in a Phase II clinical trial of JZP-8.
Samuel Saks, CEO of Jazz Pharmaceuticals, said: “Dosing of the first patient in our Phase II clinical trial and receipt of orphan drug designation are important milestones for this program.”